Cambium Bio Limited
CMB
Rank in Stocks
#32553
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on... Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Share Price
$0.31737816
Last synced: 2026-10-18
Market Cap
$9.34M
Change (1 day)
0.00%
Change (1 year)
5,917.33%
Country
AU
Trade Cambium Bio Limited (CMB)
Category
Healthcare
Dividend yield history for Cambium Bio Limited (CMB)
Cambium Bio Limited (stock symbol: CMB) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Cambium Bio Limited (CMB) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
| Year | Dividend Yield | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Dividend yields (TTM) for similar companies or competitors
| Company | Dividend Yield | Country |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
